Biopharmaceuticals are evolving from antibody drugs to innovative products.

• Eli Lilly commercialized Genetec's recombinant E. coli-based insulin synthesis technology in 1982.
• Ortho Biotech received FDA approval for its renal transplant rejection antibody treatment, Orthoclon, in 1987.
• Antibody drugs are currently achieving groundbreaking results in diseases such as cancer and rheumatoid arthritis.
• Improved antibody drugs, such as dual-targeting antibodies and antibody/drug conjugates, are on the market and under development to increase the scope and effectiveness of treatment.